Why the study?
Does drug treatment of hypertension reduce cardiovascular morbidity and mortality and is it cost-effective?
Does drug treatment of hypertension reduce cardiovascular morbidity and mortality and is it cost-effective?
Drug treatment for hypertension is effective and cost-effective, particularly in the elderly, but undertreatment remains a significant clinical issue.
Reinforces antihypertensive benefits and cost-effectiveness in elderly patients; leaves open strategies to close persistent undertreatment gaps.
A large number of prospective intervention trials have clearly demonstrated that drug treatment of hypertension lower cardiovascular morbidity and mortality. In the elderly, where treatment results in higher absolute decreases in morbidity and mortality, drug treatment is clearly cost-effective or even cost-saving in some groups of patients. Although the concept of treating hypertension is generally well accepted, a significant portion of patients remain insufficiently treated. In spite of major advances in the management of hypertension during the last decades, there is an excess morbidity and mortality in the hypertensive population. Thus, treatment is still imperfect, and a number of measures need to be taken in order to bring down cardiovascular risk in hypertensive patients to that of the normotensive population.
No takes yet. Share an insight, caveat, or question.
Thomas Hedner (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: